B.O.S.S. Retirement Advisors LLC Cuts Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• B.O.S.S. Retirement Advisors trimmed its position in IDEXX by 61.5% in Q4, selling 1,915 shares and leaving it with 1,200 shares valued at about $812,000 as of the latest 13F filing.
• Company insiders have been net sellers recently — insiders sold 45,957 shares valued at approximately $29.86 million in the last 90 days, including large sales by EVPs Nimrata Hunt and George Fennell.
• Institutional ownership is very high at 87.84%, and analyst sentiment is mixed: the consensus is a "Moderate Buy" with a $751 price target, but several firms have lowered targets (UBS to $640) or ratings recently.

B.O.S.S. Retirement Advisors LLC trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 61.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,200 shares of the company's stock after selling 1,915 shares during the quarter. B.O.S.S. Retirement Advisors LLC's holdings in IDEXX Laboratories were worth $812,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Blalock Williams LLC purchased a new position in IDEXX Laboratories during the third quarter valued at approximately $590,000. Nordea Investment Management AB increased its holdings in IDEXX Laboratories by 114.1% during the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company's stock valued at $11,283,000 after buying an additional 8,845 shares during the period. Beacon Investment Advisory Services Inc. increased its holdings in IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company's stock valued at $42,588,000 after buying an additional 6,710 shares during the period. New York State Common Retirement Fund increased its holdings in IDEXX Laboratories by 6.8% during the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company's stock valued at $38,477,000 after buying an additional 3,820 shares during the period. Finally, Mediolanum International Funds Ltd increased its holdings in IDEXX Laboratories by 14.5% during the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company's stock valued at $24,441,000 after buying an additional 4,909 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares of the company's stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 45,957 shares of company stock valued at $29,862,109. Company insiders own 0.79% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $567.46 on Monday. The company has a market cap of $45.07 billion, a price-to-earnings ratio of 43.42, a price-to-earnings-growth ratio of 3.45 and a beta of 1.58. IDEXX Laboratories, Inc. has a twelve month low of $465.00 and a twelve month high of $769.98. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company has a 50 day moving average of $589.55 and a two-hundred day moving average of $651.34.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm earned $2.53 earnings per share. IDEXX Laboratories's revenue was up 14.3% compared to the same quarter last year. As a group, analysts predict that IDEXX Laboratories, Inc. will post 14.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating for the company in a research note on Tuesday, April 28th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 target price for the company. Barclays lowered their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a research note on Thursday, February 5th. Finally, BTIG Research lowered their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.